MRSA Drugs Market With Inputs From Industry Experts 2019, Forecasts till 2022
Market Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is an antibiotic resistant strains of the pathogen. MRSA infections are classified as hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes infections such as skin infections, bone and joint infections, bacteremia, animal infections and others.
According to bulletin of the atomic scientists, about 10 million people in the US (3.6 percent of the population) are immune-compromised. The World Health Organization estimated that about 36.7 million people had HIV/AIDS worldwide in 2016. Thus, the rising immune-compromised population is expected to propel the market growth over the review period.
Additionally, growing geriatric population projected to support the growth of the market since older people are more susceptible to MRSA infections. World Health Organization estimated that during 2015-2050, the proportion of the world's population will be nearly double from 12% to 22% and by 2020, the number of people aged over 60 years likely to outnumber children younger than 5 years.
Latest Research Insights at https://www.marketresearchfuture.com/press-release/mrsa-drugs-market
Segmental Analysis:
The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.
Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.
Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).
Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Competitive Analysis:
Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.
Regional Analysis:
The Americas accounts for a significant market share owing to high expenditure on the health care. The fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.
Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing region over the assessment period.
And Many More
Brows Complete Detailed Research Report at https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312